Noémie G.
- Country
- France
- Department
- Oncology-Hematology
Research Overview
- Phase 2 Randomized Study of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide for Post-Transplant Maintenance in Newly Diagnosed Multiple Myeloma
- Phase 3 Study Evaluating Elranatamab-Lenalidomide Efficacy in Newly Diagnosed Multiple Myeloma Compared to Standard Chemotherapy and Maintenance Therapy
Data & Insights
Has run more than one trial at 28 of 69 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in treating multiple myeloma, with particular emphasis on innovative therapeutic approaches in post-transplantation maintenance therapy.
- Post-transplant maintenance strategies
- Novel therapeutic combinations
- Immunotherapy applications
The investigator explores combination therapies involving lenalidomide and targeted antibodies for optimal treatment outcomes.
Transplant Medicine
Focuses on autologous stem cell transplantation procedures and evaluating alternative consolidation strategies in multiple myeloma treatment.
- Consolidation therapy optimization
- Post-transplant care protocols
- Treatment sequencing approaches
Investigates therapeutic interventions that may potentially modify traditional transplant-based treatment paradigms.
Treatment Innovation
Studies the application of novel therapeutic agents in newly diagnosed multiple myeloma, with focus on improving response rates and patient outcomes.
- Minimal residual disease assessment
- Progression-free survival optimization
- Comparative treatment efficacy
Evaluates emerging treatment modalities against established standards of care in various treatment phases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.